India’s Longevity Market Grows, But Human Evidence Remains Thin

The Story in Brief

India’s longevity diagnostics market generated $105.6 million in 2025, against a global market of $2.8 billion, according to Grand View Research. Clinics in cities including Delhi, Mumbai, Bengaluru and Pune now offer tests covering blood biomarkers, genetics, gut microbiomes and epigenetics, alongside personalised nutrition, exercise and supplement plans.

The market remains at an early stage, with investors and clinic founders saying outcome-based care is still developing. Bengaluru entrepreneur Sowmay Jain told Brand Equity that he injects himself with a synthetic peptide to improve recovery and sleep. Steven N. Austad of the American Federation for Aging Research said there is no convincing evidence that longevity approaches work in humans. He warned that some services are unnecessary, expensive or unsupported.

The Indian Opinion

The loudest claims around longevity fall into two camps: that every test or peptide is a scam, or that better biology can be bought through premium clinics. Neither is supported by the evidence presented here. Monitoring and supervised care may have value, but self-injection and promises of near-immortality deserve strict scrutiny. The useful test is simple: which interventions produce proven health gains in controlled human studies, and at what cost?

Source: brandequity.economictimes.indiatimes.com

This story was synthesised by AI from the source linked above.

Ask their opinion on this story

They have read this article, our coverage, and the web.

Rabindranath TagoreGandhiMuhammad Ali JinnahB. R. AmbedkarJawaharlal NehruVinayak Damodar SavarkarSubhas Chandra Bose

AI simulations of historical figures. Responses are generated from the historical record, not authentic statements.